Introduction
The idea of destroying the endometrium and creating an iatrogenic 'Asherman's syndrome' as a treatment for dysfunctional bleeding is not new, with reports dating from the early twentieth century. Many attempts have been made in the past using a variety of chemical and physical agents: ethanol, formalin, copper sulphate, talc, quinacrine, fibroblast impregnated sponges, and even radiotherapy [1] . These methods were best characterized by their variable efficacy and high complication rates, and it is only since the 1980s that endometrial destruction procedures have possessed adequate efficacy and sufficient safety to compete successfully with hysterectomy as a surgical treatment.
A PubMed search (National Centre for Biotechnology Information, National Library of Medicine, USA) using the term 'endometrial ablation' in preparation for this review for the years 2000-2003 gave 175 hits. This topic has remained a very active area of research and development in gynaecological practice, and poses the question as to why this should still be the case more than 20 years after the first techniques were developed.
The so-called 'first-generation' techniques (resection, laser and rollerball) were introduced in the 1980s. They have all been extensively evaluated in national audits [2, 3] , randomized controlled trials (RCTs) [4] [5] [6] [7] and meta-analysis [8, 9 . . ]. Indeed, endometrial ablation has been described as 'one of the most carefully evaluated surgical procedures' [10] . However, despite their efficacy, the first-generation methods have a number of drawbacks. They require a skilled hysteroscopic surgeon, and despite having a significantly lower morbidity than conventional hysterectomy, the national audits demonstrated incidences of uterine perforation ranging from 0.6 to 2.5%, and fluid deficits of greater than 2 l ranging from 1 to 5% [2, 3, 11] . On the basis of these findings, there was a need to develop alternative methods that could compare with the efficacy of the first-generation techniques, but be safer and technically simpler to perform. This led to the introduction of the second-generation methods (Table 1) .
Impact of ablative surgery
For a successful technique the potential market is huge; menorrhagia is a significant healthcare problem in the developed world. In the United Kingdom alone, 5% of women of reproductive age will seek help for this symptom annually [12] , and by the end of a woman's reproductive life the risk of hysterectomy (primarily for menstrual disorders) is 20% [13] . Menorrhagia is precisely defined as a menstrual loss of more than 80 ml per month. Population studies have shown that this amount of loss is present in 10% of the population [14] , yet nearly a third of menstruating women consider their periods to be excessive [15] . This symptom thus creates a significant workload for health services and often a patient-led desire for surgical management.
Despite endometrial ablation techniques becoming an accepted part of established surgical practice, national audits of surgical practice in the United States and the UK have recently not shown the expected decrease in hysterectomy rates for dysfunctional uterine bleeding. The UK VALUE study [16 . ], a prospective nationalbased cohort of indications and complications for hysterectomies performed in the mid-1990s, showed that the largest indication for hysterectomy was dysfunctional uterine bleeding (46%); of these 50-75% could have been avoided had endometrial ablation been used. The overall operative and postoperative complication rate in the study was 3.5 and 9%, respectively, with no operative deaths. Fourteen deaths were reported within the 6-week postoperative period giving a crude mortality rate of 0.38 per thousand (95% confidence interval 0.25-0.64).
The study by Farquhar and Steiner [17 . . ] in the USA collated data from the 1990s and showed no significant decrease in the hysterectomy rate (5.6 per 1000 women in 1997), but the mode of hysterectomy had changed, the main difference being a decline in abdominal hysterectomy (still comprising 63% of hysterectomies by 1997) with a reciprocal increase in laparoscopic methods (9.9% of cases by 1997).
A UK-based study by Bridgman and Dunn [18] also examined this area, collating operative data from the National Health Service between the years 1989 and 1996. The authors found that hysterectomy rates had remained relatively steady since the introduction of endometrial ablation. The total operation rates for dysfunctional uterine bleeding initially increased, but had tended to fall since 1992/1993. The ratio of hysterectomy to endometrial ablation for dysfunctional uterine bleeding had troughed at 3 : 1 in 1992/1993, but by 1995/1996 it had increased to 4 : 1. The net effect of endometrial ablation had been to increase the total number of operations for dysfunctional uterine bleeding.
This lack of effect on hysterectomy rates may be caused by a number of factors. First, there are other examples in the literature in which surgical advances do not simply replace existing procedures, e.g. laparoscopic cholecystectomy. It is probable that women and gynaecologists view ablation as a less surgically invasive and comparably safer technique for treating dysfunctional bleeding, therefore an additional number of women who may not have been willing to undertake major surgery for their symptoms may be willing to undergo an ambulatory surgical procedure. Second, it is possible that the lack of change in the hysterectomy rate may be a reflection of the number of women requiring a second definitive procedure after a failed primary endometrial ablation.
Clinical studies
The proliferation of second-generation devices (which now number more than 10) has been a response by the surgical equipment companies to try to satisfy the (increasingly patient-led) demand for an alternative surgical treatment to hysterectomy. Unfortunately, whereas the first-generation devices had by the equivalent stage in their development undergone national-scale studies of their efficacy and complication rates, there are few comparable data on second-generation devices. This is caused by a number of factors. The equipment companies' main aim for marketing purposes is to establish quickly that their product has an equivalent or better efficacy than one of the first-generation devices. This is best proved by the accepted 'gold' standard, an RCT, and increasingly performing an RCT is a prerequisite for the product to obtain a licence for use in many western countries. All clinical studies are expensive to perform, and RCTs are particularly so. The number of treatments required in a typical RCT on endometrial ablation to have sufficient power to be statistically significant is usually approximately 300. Whereas this number can detect statistically significant differences on efficacy, it is generally too small to provide data on safety concerns. This is caused by the rarity of complications; even with the first-generation devices complications were rare (e.g. MISTLETOE quoted rates of uterine perforation of 1%) [3] . Although the second-generation devices circumvent the potential complications of fluid overload and primary haemorrhage, they are for the most part blind (the exception being hydrothermalablation). A uterine perforation with an active instrument, however infrequent, may not be recognized at the time of the procedure, with catastrophic results; a problem potentially less likely with the hysteroscopic first-generation devices. In spite of the vast number of articles on endometrial ablation, very few of the second-generation devices can give an incidence of their most potentially serious complication rate; perforation and visceral trauma [19 . ]. A notable exception to this is the microwave endometrial ablation (MEA) device, which has maintained an independent database of procedures. The figures were published in 2000 [20] , and from 1433 procedures, there was only one major complication, a small bowel burn, giving an incidence of 0.7/1000, which compares favourably with the first-generation techniques.
One of the difficulties initially encountered by the pioneer researchers into endometrial ablation was what to compare it with in order to assess its role in gynaecology. Hysterectomy (apart from sub-total) has a 100% amenorrhea rate, but has a comparatively much higher morbidity (particularly total abdominal hysterectomy) [16 . ]. Many of the original RCTs on the efficacy of endometrial ablation compared the first-generation techniques with conventional abdominal hysterectomy. This comparison has inherent problems because total abdominal hysterectomy is open surgery with a prolonged convalescence.
The recent study of Zupi et al. [21 . ] from Rome compared the relative efficacy and safety of hysteroscopic endometrial resection and laparoscopic supracervical hysterectomy in the treatment of abnormal uterine bleeding. Although laparoscopic supracervical hysterectomy is a specialist procedure, it is at least a minimally invasive type of surgery.
A total of 181 patients affected by menometrorrhagia unresponsive to medical treatment were randomly assigned to either laparoscopic supracervical hysterectomy or hysteroscopic endometrial ablation. They were monitored for 2 years to evaluate perioperative and postoperative outcomes, the resolution of symptoms, and patient satisfaction. Perhaps unsurprisingly, the operative time was significantly shorter in the hysteroscopic group, but patient satisfaction was significantly higher in the laparoscopic group.
Two recent studies compared second-generation ablation devices with the Mirena intrauterine device (IUD) [22, 23 . ]. This is a more valid comparison, as both treatments can be performed relatively quickly and involve a vaginal procedure. This was first compared with the first-generation endometrial ablation techniques by Romer [22] . The Mirena IUD has the additional benefits of being reversible, with no long-term implications for fertility.
The group of Henshaw et al. [23 . ] from Australia compared an established second-generation method (MEA) with the levonorgestrel-releasing IUD (Mirena) in a retrospective cohort-based study. This form of study is often criticized as it is difficult to eliminate bias; however, it is increasingly difficult to recruit women into RCTs for dysfunctional bleeding as they often have strong preferences for their perceived 'best' method of treatment. Recently, a UK multicentre study (Satisfaction with Mirena and Ablation: a Randomized Trial) [24] , set up to compare ablation with Mirena, had to be stopped as a result of severe recruitment problems, a situation also seen in the USA [25] .
The Australian researchers found that acceptability and satisfaction were very high for both procedures. Each treatment led to a statistically significant reduction in menstrual bleeding (P50.0001) and dysmenorrhoea scores (P50.002). The authors concluded that both treatments seem equally effective in the management of heavy menstrual loss.
A Turkish group were able to perform a small RCT of the levonorgestrel-releasing IUD and thermal balloon ablation for the treatment of menorrhagia (72 women) [26 . ]. Soysal et al. [26 . ] found that both techniques were effective in reducing menstrual blood loss, but that thermal balloon ablation was more effective in decreasing pictorial blood loss sores. Patients treated by thermal balloon ablation also reported fewer side-effects and perceived a higher health-related quality of life in physical role functioning.
Long-term data for first-generation devices
There are now women who have had an endometrial ablation procedure for approximately 20 years Fortunately a significant number of those women involved in the early clinical trials have been followed-up, providing a wealth of quality information on long-term outcomes and complication rates.
The data available for the first-generation methods show that most treatment failures occur within 12-24 months of the initial treatment [27 . -29 . ]. Surgical success depends on a number of prognostic factors; in women with a relatively large uterus (10 cm), those with myomas or polyps, and patients with dysmenorrhea, the success rate tends to be lower. Previous tubal ligation has also been shown to be a risk factor [30 . ] (often attributed to residual endometrium creating a haematometra; the post-ablation tubal sterilization syndrome). A recent paper also examined psychiatric morbidity after endometrial ablation and its association with genuine menorrhagia [31 . ]. The authors found that women with the best psychiatric outcome (6% postoperative psychiatric morbidity) were those with genuine menorrhagia and low psychiatric morbidity pre-operatively. Those who fared worst (39% postoperative psychiatric morbidity)
were women with high pre-operative psychiatric morbidity and low menstrual blood loss.
Pre-treatment with gonadotrophin-releasing hormone (GnRH) analogues has been demonstrated in a Cochrane review [32 . . ] to be associated with a shorter duration of surgery, greater ease of surgery and a higher rate of postoperative amenorrhoea at 12 months with hysteroscopic resection or ablation. Other findings from the meta-analysis were that postoperative dysmenorrhoea appeared to be reduced. The use of GnRH analogues had no effect on intra-operative complication rates, and patient satisfaction with surgery was irrespective of the use of any endometrial thinning agents. Compared with Danazol, the other commonly used agent for endometrial preparation, GnRH analogues produced more consistent endometrial atrophy. However, for other intra-operative and postoperative outcomes, any differences between the use of endometrial thinning agents were minimal, and there was no benefit with GnRH analogue pretreatment in the one small study in which women had a thermal balloon procedure [33] . GnRH analogues and Danazol do produce side-effects in a significant proportion of women, although few studies report these in detail, a fact that should always be discussed with the patient before drug administration.
One of the tenets of endometrial ablation was that a histological sample of endometrium should be obtained before surgery to ensure that there was no malignant or pre-malignant cause for the bleeding, as an endometrial ablative procedure on its own would not be adequate treatment, and could potentially delay diagnosis [34] . The group of Vilos et al. [35 . ] in Canada have performed resectoscopic surgery in 32 high surgical risk women with endometrial hyperplasia (both simple and complex) without atypia. Of those women with complex non-atypical hyperplasia (n = 7), five underwent complete endomyometrial resection. Follow-up of these five women for between 1 and 7 years gave 100% amenorrhoea, and no evidence of progression to endometrial cancer. The authors contentiously stated in their discussion (and in a further paper [36 . ]) that given the lack of consensus regarding the best way to treat simple and complex non-atypical hyperplasias, and the inherent false-negative diagnoses with performing pipelle endometrial samples, they advocate and routinely perform endomyometrial resection (rather than ablation) on women with abnormal uterine bleeding who have risk factors for endometrial hyperplasia and cancer.
The originators of the MEA technology (Sharp, UK) have an interesting case report using MEA in a woman with endometrial cancer [37 . ] with high-risk factors for conventional surgery.
Long-term data for second-generation devices
Of the second-generation devices, there are now longterm data available for MEA and ThermaChoice from their respective randomized controlled trials [38 . . ,39
. . ]. These compare favourably with the data from firstgeneration devices; MEA [38 . . ] has 2-year follow-up data, which show persistent patient satisfaction and quality of life scores. The hysterectomy rates of the study had plateaued at 2 years (11.6% after microwave endometrial ablation and 12.7% after transcervical endometrial resection), with no repeat endometrial ablative procedures required. ThermaChoice [39 . . ] now has 5-year follow-up from its original RCT data. A total of 122 women of the 255 participants in the original study were available for follow-up; 58 of the women (95%) undergoing ThermaChoice uterine balloon therapy (UBT), and 59 (97%) having rollerball ablation reported normal or less bleeding. Similarly, 93 and 100%, respectively, were satisfied with the procedure. Among the total population of 255 women, 42 hysterectomies (21 UBT, 21 rollerball), five repeat ablations (three UBT, two rollerball), and one dilatation and curettage (rollerball) were reported by the fifth year. Nearly seven out of 10 women were cured of menorrhagia without additional intervention 5 years after ablation. The authors concluded that ThermaChoice continues to be an effective, simple treatment of menorrhagia, with clinical outcomes similar to those of rollerball ablation at 5-year follow-up.
A meta-analysis of the two methods of endometrial ablation (first-versus second-generation) by the Cochrane group [9 . . ] has provided validity for the newer techniques. The reviewers (Lethaby and Hickey [9 . . ]) found that in general the newer devices took less time to perform an ablation, they were more likely to be performed under local anaesthesia, but had a greater chance of equipment failure. From an efficacy perspective, the reduction in menstrual bleeding did not differ significantly between any of the groups, and the reviewers concluded that overall, the existing evidence suggests that success rates and complication profiles of the newer techniques of ablation compare favourably with transcervical resection of the endometrium, although the technical difficulties with the new equipment need to be ironed out.
Conclusion
The question of which treatment is best is a complex one and involves balancing patients' wishes, expected outcomes, complications, cost effectiveness and quality of life issues. Within the context of techniques for endometrial ablation, the second-generation devices are quicker and easier to perform with equivalent efficacy to the first-generation methods in randomized trials. How-ever, they are usually contraindicated in uteri with fibroids or other anomalies, have the drawback of often not directly visualizing the endometrial cavity, and are relatively expensive.
These operations are mainly performed on women with a benign condition; dysfunctional uterine bleeding, therefore safety is a priority. National cohort studies validated the first-generation devices, but there are few equivalent data for the newer techniques, leaving a gap in knowledge that must be filled.
The anticipated decline in hysterectomy rates with the advent of endometrial destruction methods has not occurred, and this may indicate a lower threshold for surgical management. However, endometrial ablation is here to stay; it has been scrutinized, randomized and meta-analysed, with consistently reassuring results. The introduction of the newer ablative methods is likely to boost further the uptake and use of this as a surgical treatment of menorrhagia, but it is foreseeable that with the increased use of these simpler procedures, conventional first-generation methods may only continue to be utilized within the remit of specialist centres, as they will tend to be performed for particular indications.
